BLFS
BioLife Solutions, Inc. Healthcare - Medical Instruments & Supplies Investor Relations →
BioLife Solutions, Inc. (BLFS) closed at $26.04 as of 2026-06-19, trading 21.0% above its 200-week moving average of $21.52. The stock is currently moving closer to the line, down from 21.4% last week. With a 14-week RSI of 81, BLFS is in overbought territory.
Trading volume is running at 1.7x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.14 ratio) is neutral — neither side is clearly dominating.
Over the past 1860 weeks of data, BLFS has crossed below its 200-week moving average 24 times. On average, these episodes lasted 52 weeks. Historically, investors who bought BLFS at the start of these episodes saw an average one-year return of +58.8%.
With a market cap of $1272 million, BLFS is a small-cap stock. The company generates a free cash flow yield of 0.5%. Return on equity stands at -3.1%. The stock trades at 3.4x book value.
Share count has increased 12.5% over three years, indicating dilution.
Over the past 33.5 years, a hypothetical investment of $100 in BLFS would have grown to $5, compared to $3097 for the S&P 500. BLFS has returned -8.7% annualized vs 10.8% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: BLFS vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After BLFS Crosses Below the Line?
Across 23 historical episodes, buying BLFS when it crossed below its 200-week moving average produced an average return of +15.7% after 12 months (median +0.0%), compared to +15.5% for the S&P 500 over the same periods. 48% of those episodes were profitable after one year. After 24 months, the average return was +31.7% vs +27.5% for the index.
Each line shows $100 invested at the moment BLFS crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. BLFS currently has negative free cash flow, so price-based dislocation levels are not available. The score still tracks yield deviation from baseline.
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from BLFS's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
BLFS has crossed below its 200-week MA 24 times with an average 1-year return of +58.8% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Oct 1990 | Jan 1991 | 13 | 18.8% | +744.4% | -78.0% |
| Jun 1993 | Feb 2000 | 350 | 95.2% | -48.6% | -92.0% |
| Mar 2000 | Sep 2000 | 27 | 44.1% | -82.8% | -17.9% |
| Oct 2000 | Jun 2005 | 245 | 95.8% | -93.6% | +48.8% |
| Jul 2005 | Jul 2005 | 3 | 7.5% | -35.7% | +1228.6% |
| Sep 2005 | Apr 2007 | 84 | 53.3% | -28.6% | +1228.6% |
| Jun 2007 | Jan 2009 | 85 | 67.8% | -54.5% | +1590.9% |
| Feb 2009 | Feb 2009 | 1 | 20.9% | +42.9% | +2557.1% |
| Mar 2009 | Mar 2009 | 1 | 43.4% | +120.0% | +3620.0% |
| Apr 2009 | May 2009 | 3 | 30.8% | N/A | +2225.0% |
| Jan 2010 | Feb 2010 | 1 | 7.7% | -12.5% | +2225.0% |
| Apr 2010 | May 2010 | 6 | 31.7% | +12.5% | +2225.0% |
| Jun 2010 | Feb 2011 | 38 | 42.7% | +33.3% | +3000.0% |
| Mar 2011 | Apr 2011 | 3 | 4.7% | +25.0% | +2225.0% |
| Apr 2011 | Mar 2012 | 46 | 62.6% | N/A | +2225.0% |
| Apr 2012 | Jul 2012 | 13 | 14.5% | +385.7% | +2557.1% |
| Apr 2014 | Jul 2017 | 167 | 61.6% | -28.7% | +846.9% |
| Mar 2020 | Apr 2020 | 5 | 4.6% | +320.5% | +188.4% |
| Feb 2022 | Nov 2024 | 144 | 63.7% | +4.8% | +15.5% |
| Feb 2025 | Mar 2025 | 1 | 1.3% | +0.8% | +8.5% |
| Mar 2025 | Apr 2025 | 3 | 13.5% | -6.6% | +24.7% |
| May 2025 | Aug 2025 | 13 | 7.4% | -5.4% | +11.8% |
| Mar 2026 | Apr 2026 | 6 | 13.2% | N/A | +31.1% |
| Apr 2026 | May 2026 | 3 | 3.0% | N/A | +22.8% |
| Average | 52 | — | +58.8% | — |
Frequently Asked Questions
Is BLFS below its 200-week moving average?
No. BioLife Solutions, Inc. (BLFS) is currently 21.0% above its 200-week moving average of $21.52. It would need to fall to $21.52 to cross below the line.
What is BLFS's 200-week moving average price?
BioLife Solutions, Inc.'s 200-week moving average is $21.52 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when BLFS drops below its 200-week moving average?
BLFS has crossed below its 200-week moving average 24 times in our data. On average, buying at that moment produced a one-year return of +58.8%. These dips have historically been decent entry points. These episodes lasted 52 weeks on average.
Is BLFS a good value right now?
Here's what our data says about BLFS as of 2026-06-19: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 81 (overbought). Free cash flow yield is 0.5%. Return on equity is -3.1%. Price-to-book is 3.4x. This is not a buy or sell recommendation — always do your own research.
How does BLFS compare to the S&P 500?
Over the past 33.5 years, $100 invested in BLFS would have grown to $5, compared to $3097 for the S&P 500. That's -8.7% annualized vs 10.8% for the index. BLFS has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19